Janssen bags USFDA nod for psoriatic arthritis treatment STELARA for pediatric patients - Video

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (USFDA) has approved STELARA (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA).

This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis. Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate to severe plaque psoriasis (PsO).